Spectrophotometric Bivariate Method for Determination of Candesartan Cilexetil in Presence of its Alkaline Induced Degradation Product

NAWAL AL-ARFAJ, WEDAD AL-ONAZI* and AMINA AL-BRASHY

Department of Chemistry, College of Science, (Girls Section), King Saud University, P.O. Box 22452, Riyadh-11495, Saudi Arabia

*Corresponding author: E-mail: walonazi@yahoo.com

(Received: 20 August 2011;

Accepted: 14 August 2012)

AJC-11963

A simple, sensitive, selective and precise stability -indicating method for the determination of candesartan cilexetil in presence of its alkaline degradate and in tablets was developed and validated. The method is based on determination of candesartan cilexetil by the bivariate calibration depending on simple mathematic algorithm which provide simplicity and rapidity. The method showed good linearity in the range of 1- 12 $\mu\text{g mL}^{-1}$ at 225 and 2-12 $\mu\text{g mL}^{-1}$ at 250 nm with mean percentage recovery 100.29 ± 0.64 . Candesartan cilexetil can be determined in the presence of up to 80 % of its alkaline degradate, the selectivity of the method was checked using laboratory prepared mixtures. The proposed method has been successfully applied to the analysis of candesartan cilexetil in bulk and in commercial tablets without interference from additives or excipients and the results were satisfactory compared with a reference method. Also, the suggested method was successfully applied to the content uniformity testing and degradation kinetic study.

Key Words: Candesartan cilexetil, Candesartan, Stability-indicating, Bivariate method.

INTRODUCTION

Candesartan cilexetil belongs to the class of angiotensin receptor antagonists and acts by binding selectivity and non-competitively to angiotensin II receptor type I, thus preventing actions of angiotensin II.

Candesartan cilexetil (CC); m.f. $\text{C}_{33}\text{H}_{34}\text{N}_6\text{O}_6$; m.w. 610.67

The drug finds most significant clinical use in the treatment of hypertension of all grades¹. Chemically, candesartan cilexetil is an ester prodrug of its active metabolite candesartan (C.V.11974), to which it owes its therapeutic effect, by the action of some endogenous esterases².

The chemical stability of candesartan cilexetil has been studied in plasma and bioanalytical samples³. Under these conditions the drug was found to be susceptible to hydrolysis

resulting the removal of cilexetil moiety. Few methods for the determination of candesartan cilexetil have been reported in literature. HPLC methods were reported for determination of candesartan cilexetil or candesartan with some angiotensin II receptor antagonists with or without hydrochlorothiazide as a diuretic drug⁴⁻⁶. Also, HPLC methods were reported for determination of candesartan cilexetil in tablets as a single component^{3,7-9}, in combination with candesartan and a metabolite (M II)¹⁰ in human plasma and urine and with hydrochlorothiazide simultaneously in pharmaceutical formulations¹¹⁻¹³.

Capillary electrophoresis methods were reported for simultaneous analysis of several angiotensin II receptor antagonists including candesartan cilexetil¹⁴⁻¹⁷. Other methods such as voltametry¹⁸⁻²⁰ and HPTLC-densitometry²¹ were reported for determination of candesartan cilexetil.

The only spectrophotometric methods reported for determination of candesartan cilexetil were the first order derivative for it in tablets²² as a single component or simultaneously with hydrochlorothiazide²³ or for simultaneous determination of candesartan and hydrochlorothiazide in tablets²⁴.

No stability-indicating methods are reported in literature for determination of candesartan cilexetil in presence of its alkaline degraded product, candesartan. The scientific novelty of the present work is that the suggested spectrophotometric bivariate method is simple, rapid, selective, less expensive and

less time consuming compared with other published chromatographic methods. The focus of the present work study was to develop and validate a simple stability - indicating method for determination of candesartan cilexetil in presence of its alkaline degradate (candesartan) for the quality control of candesartan cilexetil in its dosage forms.

EXPERIMENTAL

The spectrophotometric measurements were made with Ultrospec 2000, UV/VIS spectrophotometer, Amersham Pharmacia Biotech with Swift II Application, Biochrom Ltd, Cambridge UK. The solutions were recorded in 1 cm matched quartz cells against methanol as a solvent blank over the range 200–400 nm.

Pure standard: Candesartan cilexetil was kindly supplied from Jazeera Pharmaceutical Industries(JPI) Riyadh, Saudi Arabia. It was used as received without purification (its purity was 99.98 %).

Pharmaceutical dosage forms: Atacand 16 tablets, manufactured by AstraZeneca - Egypt under license of Astra Zeneca, Sweden. The Batch No. was 90123. Candesar 8 tablets, produced by PHARAONIA Pharmaceuticals, Pharo Pharma (Egypt), under license of Takeda Pharmaceutical Company Ltd. The Batch No. was 1409002.

Degraded product: 0.4 g of candesartan cilexetil powder was transferred into 250 mL stoppered flask, dissolved in 25 mL methanol, completed to 100 mL with 2 N NaOH and refluxed with stirring at 80 °C for 3 h. Complete hydrolysis was followed *via* TLC using chloroform/methanol (80/20 v/v) as a developing system. The solution was neutralized with 4 N HCl solution till pH 3, then the degradate was extracted with chloroform 6 mL $\times$ 20 mL). The extract was evaporated at room temperature and the degradate powder was collected and elucidated by IR spectroscopy.

All chemicals used throughout this work (methanol, chloroform, HCl and NaOH) were of BDH, Poole, UK and the solvents were of spectroscopic grade.

Standard solutions: Stock standard solutions of candesartan cilexetil and its alkaline degradate containing 1 mg mL⁻¹ were prepared separately in methanol. Working solutions were prepared (100 μ g mL⁻¹) by suitably diluting the stock standard solutions.

Laboratory prepared mixtures: Solutions containing different ratios of candesartan cilexetil and its alkaline product were prepared to contain 20–80 % of alkaline degradate.

Procedure

Construction of calibration graphs for the bivariate spectrophotometric method: Into two separate sets of 10 mL volumetric flasks, aliquots equivalent to 10–120 μ g mL⁻¹ of candesartan cilexetil and its alkaline degradate were transferred from their working solutions (100 μ g mL⁻¹) in methanol. The volume was completed with methanol. The regression equations, at 225 and 250 nm, for candesartan cilexetil and its alkaline degradate were computed.

Analysis of bulk substance: The method mentioned above was applied to the determination of the purity of candesartan cilexetil raw material and the percent recoveries were calculated by application in the bivariate equations.

Analysis of pharmaceutical dosage forms: Fourteen tablets of each *i.e.*, Candesar-8 tablets and Atacand-16 tablets were powdered and mixed well; an accurately weighed amount of the powder equivalent to 50 mg of candesartan cilexetil of each was transferred into two separate 100 mL volumetric flasks. 75 mL of methanol were added, sonicated for 0.5 h, completed to volume with methanol, to obtain 0.5 mg/mL stock solution and filtered. The solution was diluted to the same concentrations of the appropriate working solutions and proceeded according to the procedure mentioned above. The nominal content of candesartan cilexetil in each tablets was calculated from application in the bivariate equations.

Content uniformity testing: The same procedure applied for the analysis of candesartan cilexetil in tablets was followed using one tablet as a sample. Ten tablets were analyzed and the uniformity of their contents was tested by applying the official of USP guidelines.

Stability study of the degradation products: A stock solution of 400 mg/mL of candesartan cilexetil was prepared in methanol. Aliquots of this solution (10 μ g mL⁻¹) were transferred into 10 mL volumetric flasks, 3 mL aliquots of 0.1 M NaOH or 0.1 M HCl were added. These volumetric flasks were placed in thermostated water bath at different temperatures (50, 70, 80, 90 °C) for different time intervals (10, 20, 30 min).

At the specified time intervals, the content of each flask were cooled, neutralized to pH 7 using predetermined volumes of 0.1 M HCl or 0.1 M NaOH. The volume was completed to the mark with methanol and analyzed by the bivariate method as before.

RESULTS AND DISCUSSION

Candesartan is marketed as the cyclohexyl 1-hydroxyethyl carbonate (cilexetil) ester, known as candesartan cilexetil. Candesartan cilexetil is metabolized completely by esterases in the intestinal wall during absorption to the active candesartan moiety (the use of a prodrug form increases the bioavailability of candesartan). Upon refluxing candesartan cilexetil with alkali, the carboxylic acid (candesartan) was obtained.

So the determination of candesartan cilexetil in presence of its alkaline degradation was essential.

The International Conference on Harmonization (ICH) guideline entitled "stability testing of new drugs substances and products" requires the stress testing to be carried out to elucidate the inherent stability characteristics of the active substances²⁵. An ideal stability- indicating method is one that quantifies the standard drug alone and also resolves its degradation products. The structure of the alkaline degradate was elucidated by IR. The IR spectrum of candesartan cilexetil showed a characteristic band at 1750 cm⁻¹, indicating the presence of carbonyl group while the IR spectrum of the degradate showed the same band but shifted to 1705 cm⁻¹ and a new broad band at 3388 cm⁻¹ indicating the presence of a hydroxyl group of the carboxylic acid (due to hydrolysis, Fig. 1). Only one spot of the degraded product seen on TLC under UV lamp (254 nm) with R_f = 0.24 (R_f for candesartan cilexetil was 0.78).

Fig. 1. IR spectra of candesartan cilexetil (A) and its degradation product candesartan (B) in methanol

The focus of the present work was to develop an accurate, specific, reproducible and sensitive stability-indicating method for the determination of candesartan cilexetil in presence of degradation product. The zero order absorption spectra of candesartan cilexetil and its alkaline degradate showed similarity and severe over-lapping (Fig. 2) which interfere with the direct determination of candesartan cilexetil. In the present work, candesartan cilexetil was determined and resolved from its alkaline degradate by using the bivariate calibration spectrophotometric method^{26,27}. The method is based on a simple

mathematic algorithm, in which the data used derives from four linear regression calibration equations: Two calibrations for each component at two wavelengths selected using the method of Massart *et al.*²⁸. The method has been successfully applied to resolve different binary mixtures, such as nifuroxazide and drotaverine HCl²⁹. The advantages of bivariate calibration method is its simplicity and the fact that derivatization procedures are not necessary; unlike other chemometric techniques, there is no need for full spectrum information and no data processing is required.

Fig. 2. Absorption spectra of candesartan cilexetil (a), candesartan (b) 10 µg mL⁻¹ each in methanol and their mixture (c)

The linear calibration regression function for the spectrophotometric determination of an analyte A, at a selected wavelength (i) is given by:

$$A_{A_i} = m_{A_i} \cdot C_A + e_{A_i}$$

where m_{A_i} is the slope of linear regression, C_A is the concentration of analyte A and e_{A_i} is the intercept value. If the measurements for the binary mixture (A,B) are performed at two selected wavelengths (λ_1 , λ_2) we have a two equations set:

$$A_{AB_1} = m_{A_1} C_A + m_{B_1} C_B + e_{AB_1}$$

$$A_{AB_2} = m_{A_2} C_A + m_{B_2} C_B + e_{AB_2}$$

The resolution of such equations set allows the evaluation of C_A and C_B values:

$$C_A = \frac{m_{B_2} (A_{AB_1} - e_{AB_1}) + m_{B_1} (e_{AB_1} - A_{AB_2})}{m_{B_2} m_{A_1} - m_{B_1} m_{A_2}}$$

$$C_B = \frac{A_{AB_1} - e_{AB_1} - m_{A_1} C_A}{m_{A_1}}$$

where e_{AB_1} and e_{AB_2} are the sum of the intercepts of the linear calibration regression equations at the selected two wavelengths ($e_{AB_1} = e_{A_1} + e_{B_1}$), m_A and m_B are the slopes of the linear regression equations at the two selected wavelengths and C is the concentration of candesartan cilexetil and its alkaline degradate.

These simple mathematic algorithms allow the resolution of the two compounds by measuring the absorbance of candesartan cilexetil and its degradate at the two wavelengths and using the parameters of the linear regression functions evaluated individually for each component at the same

TABLE-1
APPLICATION OF THE METHOD OF KAISER FOR THE SELECTION OF
THE WAVELENGTH SET FOR THE DETERMINATION OF CANDESARTAN CILEXETIL

λ_1/λ_2	225	230	235	240	245	250	255	260	265
225	0	13.24	33.19	38.19	37.96	40.60	38.18	30.30	14.0
230	–	0	18.58	23.80	23.70	25.37	23.30	17.50	5.5
235	–	–	0	6.08	6.10	6.62	4.90	1.33	5.8
240	–	–	–	0	0.13	1.77	1.32	4.03	9.28
245	–	–	–	–	0	0.43	1.44	4.1	9.27
250	–	–	–	–	–	0	1.56	4.42	9.9
255	–	–	–	–	–	–	0	2.97	8.79
260	–	–	–	–	–	–	–	0	5.89
265	–	–	–	–	–	–	–	–	0

The absolute values of determinations of sensitivity ($K \times 10^{-5}$). The bold value represent the highest matrix determinant value obtained at the wavelength set 225 and 250.

wavelengths. The method of Massart *et al.*²⁸ was used for the selection of optimum wavelength set which assured the best sensitivity for the quantitative determination of the cited drug. In order to apply this method, select the signals of the two components locate (225, 230, 235, 240, 245, 250, 255, 260 and 265 nm) wavelengths. The calibration curve equations and their respective linear regression coefficients are obtained directly with the aim of ensuring the linearity between the signal and the concentrations. The slope values of the linear regression were estimated for the drug and its alkaline degradate at the selected wavelengths and used for the determination of the sensitivity matrices K, proposed by Massart *et al.*²⁸. A series of sensitivity matrices K, were calculated for each binary mixture and for every pair of the pre-selected wavelengths:

$$K = \begin{pmatrix} m_{B_1} & m_{A_1} \\ m_{B_2} & m_{A_2} \end{pmatrix} \quad (\text{A is CC, B is the degradate})$$

where $m_{A_{1,2}}$ and $m_{B_{1,2}}$ are the sensitivity parameters (slope) of the regression equations of A and B at the two selected wavelengths (225, 250 nm). The determinants of these matrices were calculated and shown in Table-1. The wavelength set was selected for which the highest matrix determinant value was obtained.

For bivariate determination of candesartan cilexetil in presence of its degradate, 225 and 250 nm were used; at these selected wavelengths the one-component calibration curves were obtained in the range of 2-12 $\mu\text{g mL}^{-1}$ for candesartan cilexetil and its alkaline degradate, using the following linear regression calibration formula:

For CC $A = 0.0037 + 0.0623 C$ ($r = 0.9997$) at 225 nm

$A = 0.0005 + 0.030 C$ ($r = 0.9992$) at 250 nm

For Deg. $A = 0.0043 + 0.0763 C$ ($r = 0.9999$) at 225 nm

$A = 0.0067 + 0.0414 C$ ($r = 0.9996$) at 250 nm

where A is the absorbance at the selected wavelength, C is the concentration in $\mu\text{g mL}^{-1}$ and (r) is the regression coefficient.

Different solvents were tried to resolve their overlapping as methanol, ethanol, butanol, acetonitrile, 0.05 N NaOH and 0.05 N HCl, the best regression calibration lines were obtained in methanol solvent.

Validation of the method

Concentration ranges and calibration graphs: Under the above described experimental conditions, linear relation-

ship were established by plotting the concentration of candesartan cilexetil and the alkaline degradate against absorbance at 225 and 250 nm in the range of 1-12 $\mu\text{g mL}^{-1}$ for 225nm and 2-12 $\mu\text{g mL}^{-1}$ at 250 nm. The high values of correlation coefficient (r) and small intercepts indicate good linearity of the calibration graphs. Statistical analysis of the candesartan cilexetil data gave small values of the standard deviation of the residuals ($S_{Y/X}$), of slop (S_b), of intercept (S_a) and the RSD (%) and relative error (%) (Er %) (Table-2).

TABLE-2
PERFORMANCE DATA OF THE PROPOSED
BIVARIATE METHOD FOR THE DETERMINATION
OF CANDESARTAN CILEXETIL

Parameter	Values	
	At 225 nm	At 250 nm
Range	1-12 $\mu\text{g L}^{-1}$	2-12 $\mu\text{g mL}^{-1}$
Slope	0.0623	0.03
Intercept	0.0037	0.0005
Correlation coefficient	0.9997	0.9992
LOD	0.28	0.42
LOQ	0.86	1.27
$S_{Y/X}$ (Standard deviation of residuals)	7.4039×10^{-4}	1.397×10^{-4}
S_a (Standard deviation of intercept)	0.0038	0.00535
S_b (Standard deviation of slope)	7.4039×10^{-4}	5.26356×10^{-4}

Limit of quantitation (LOQ) and limit of detection (LOD): The limit of quantitation was determined by establishing the lowest concentration that can be measured according to ICH Q 2 B recommendation³⁰ below which the calibration graph is none linear and the limit of detection was determined by establishing the minimum level at which the analyte can be reliably detected ($S/N = 3$). The values are demonstrated in Table-2.

Accuracy and precision: The proposed method was evaluated by studying the accuracy as percent relative error (Er %) and precision as percent relative standard deviation (RSD %) using three preparations with suitable concentration, as shown in Table-3, the intraday ($n = 3$) and interday ($n = 3$) accuracy calculated as error (%) was found to be 0.36-0.47 and 0.22-0.33 % for candesartan cilexetil, respectively. The repeatability of the assay was found to be within 0.63-0.82 % ($n = 3$) at 4, 8 and 12 $\mu\text{g mL}^{-1}$. The reproducibility of the assay at the same concentration levels was found to be 0.38-0.65 % ($n = 3$).

TABLE-3
ACCURACY AND PRECISION DATA FOR CANDESARTAN
CILEXETIL USING THE PROPOSED BIVARIATE METHOD

Parameter	CC concentration ($\mu\text{g mL}^{-1}$)		
	4	8	12
Intraday % recovery	99.52 100.60 99.49	100.28 98.98 99.76	101.08 99.55 100.80
Mean $\pm$ SD	99.87 $\pm$ 0.63	99.67 $\pm$ 0.65	100.48 $\pm$ 0.82
RSD (%)	0.63	0.65	0.81
Er (%)	0.36	0.38	0.47
Interday % recovery	101.14 100.06 100.28	98.74 99.77 99.93	99.61 100.10 100.35
Mean $\pm$ SD	100.49 $\pm$ 0.57	99.48 $\pm$ 0.65	100.02 $\pm$ 0.38
RSD (%)	0.57	0.65	0.38
Er (%)	0.33	0.38	0.22

NB: Each result is the average of three separate determinations.
Intraday: within the day. Interday: consecutive days.

Applications

Determination of candesartan cilexetil bulk material:

The results of the proposed method for determination of the purity of candesartan cilexetil were favourably compared with those obtained using the reference method²². The latter method depends on measuring the first derivative (D^1) of candesartan cilexetil, as a single component at 270 nm. Statistical analysis of the results obtained by the proposed and reference methods showed no significant differences in the performance of the 2 methods using the Student's *t*-test and Variance ratio, F-test (Table-4)³¹. The proposed procedure offers additional advantages over the reference procedure in that the proposed is more sensitive with good accuracy and precision and considered as a stability-indicating method for determination of candesartan cilexetil in presence of its alkaline degradation product.

Analysis of laboratory prepared mixtures: The absorption spectra of different prepared mixtures were measured at 225 and 250 nm, the concentration of candesartan cilexetil was calculated using the parameters of the linear regressions function evaluated for candesartan cilexetil and its degradate at the same wavelengths and substituting in the previous equations for C_A and C_B . The results obtained in Table-5 showed that the method is valid for the determination of candesartan cilexetil in presence of up to 80 % of its alkaline degradate.

Tablet analysis: The proposed bivariate method was applied to the determination of candesartan cilexetil in its

TABLE-5
DETERMINATION OF CANDESARTAN CILEXETIL IN
LABORATORY PREPARED MIXTURES BY THE PROPOSED
BIVARIATE SPECTROPHOTOMETRIC METHOD

Alkaline product		Candesartan cilexetil		
Added ($\mu\text{g mL}^{-1}$)	%	Taken ($\mu\text{g mL}^{-1}$)	Found ($\mu\text{g mL}^{-1}$)	Found (%)
2	20	8	7.994	99.93
4	40	6	5.938	98.97
6	50	6	6.050	100.83
6	60	4	3.986	99.65
8	80	2	2.016	100.80
Mean $\pm$ SD	—	—	—	100.04 $\pm$ 0.79

N.B. Each result is the average of three separate determinations.

commercial tablets, the results were shown in Table-6. The validity of the method was assessed by applying the standard addition technique (Table-7), the results of analysis of the commercial tablets and the recovery study (standard addition method) suggested that there are no interference from any excipients which are normally present in tablet formulations. The results for the determination of candesartan cilexetil in tablets obtained by the proposed method were compared with the D^1 method²². Statistical analysis of the results was performed with regard to accuracy and precision using student *t*-test and F-ratio; as presented in Table-6, there is no significant difference between the proposed and the reference methods with regard to accuracy and precision³¹.

Content uniformity testing: Due to the high precision of the proposed method and its ability to rapidly estimate the concentration of CC in a single tablet extract with sufficient accuracy, the method is ideally suited for content uniformity testing which is a time consuming process when using conventional assay techniques. The steps of the test were adopted according to the USP³² procedure. The acceptance value (AV) was calculated for each of the commercially available tablets and it was found to be smaller than the maximum allowed acceptance value (LI). The results demonstrated excellent drug uniformity, as shown in Table-8.

Degradation kinetic study: Degradation of candesartan cilexetil with either NaOH or HCl was found to be temperature dependent (Fig. 3). The apparent first order degradation rate content and $t_{1/2}$ times at each temperature were calculated for NaOH degradation and given in Table-9. Plotting $\ln K$ observed values *versus* $1/T$, Arrhenius plot was obtained (Fig. 4).

TABLE-4
STATISTICAL ANALYSIS OF THE RESULTS OBTAINED BY THE PROPOSED AND REFERENCE METHODS

Parameter	Proposed method			Ref. method ²²	
	Taken ($\mu\text{g mL}^{-1}$)	Found ($\mu\text{g mL}^{-1}$)	Found (%)	Taken ($\mu\text{g mL}^{-1}$)	Found (%)
	2	2.017		8	100.38
	4	4.050	100.85	16	99.17
	6	5.982	101.25	24	100.01
	8	7.983	99.70	28	101.70
	10	9.983	99.79	32	101.34
	12	12.038	100.32	38	101.32
n	6			6	
Mean $\pm$ SD	100.29 $\pm$ 0.64			100.65 $\pm$ 0.97	
Variance	0.41			0.94	
Student's <i>t</i> -value	0.75 (2.228)			—	
Variance ratio F-value	2.29 (5.05)*			—	

*Tabulated values at $p = 0.05$ ³¹.

TABLE-6
ASSAY OF CANDESARTAN CILEXETIL IN FORMULATION USING THE PROPOSED AND REFERENCE METHODS

Parameter	Proposed method			Ref. method ²²	
	Taken ($\mu\text{g mL}^{-1}$)	Found ($\mu\text{g mL}^{-1}$)	Found (%)	Taken ($\mu\text{g mL}^{-1}$)	Found (%)
Atacand-16	6	5.991	99.85	10	99.35
Tablets	8	8.034	100.43	16	99.47
	10	9.967	99.67	24	100.43
	12	12.032	100.27	30	100.70
Mean $\pm$ SD	—	—	100.06 $\pm$ 0.35	—	99.99 $\pm$ 0.68
Student's- <i>t</i> -value	—	0.13	—	—	—
Variance ratio F-value	—	3.77	—	—	—
Candesar-8	6	6.046	100.77	10	99.88
Tablets	8	7.938	99.23	16	100.70
	10	10.033	100.33	20	100.35
	12	11.926	99.38	30	100.57
Mean $\pm$ SD	—	—	99.93 $\pm$ 0.74	—	100.13 $\pm$ 0.63
Student's- <i>t</i> -value	—	0.41	—	—	—
Variance ratio F-value	—	1.38	—	—	—

N. N.B. Each result is the average of three separate determinations. Tabulated *t*-test and F test are 2.45 and 9.28 at $p = 0.05$, respectively³¹.

TABLE-7
ASSAY OF CANDESARTAN CILEXETIL IN FORMULATION BY APPLICATION OF STANDARD ADDITION METHOD USING THE PROPOSED BIVARIATE METHOD

Preparation	Amt. taken ($\mu\text{g mL}^{-1}$)	CC added ($\mu\text{g mL}^{-1}$)	Amt found ($\mu\text{g mL}^{-1}$)	Found (%)
Atacand-16	2	4	5.968	99.47
Tablets	4	6	9.971	99.71
	6	2	7.905	98.81
	6	6	12.016	100.13
Mean $\pm$ SD	—	—	—	99.53 $\pm$ 0.55
Candesar-8	2	4	5.953	99.22
Tablets	4	6	9.843	98.43
	6	2	7.936	99.20
	6	6	12.018	100.15
Mean $\pm$ SD	—	—	—	99.25 $\pm$ 0.70

N.B. Each result is the average of three separate determinations.

TABLE-8
RESULTS OF CONTENT UNIFORMITY TESTING OF CANDESARTAN CILEXETIL TABLETS USING THE PROPOSED BIVARIATE METHOD

Parameter	Percentage of the label claim	
	Candesar 8	Atacand 16
Data	99.51	100.55
	101.14	99.49
	100.22	98.98
	99.55	100.60
	100.94	100.54
	99.52	100.35
	98.74	99.76
	99.77	100.12
	99.93	101.08
	100.54	99.61
Mean $\pm$ SD	99.99 $\pm$ 0.73	100.11 $\pm$ 0.64
RSD (%)	0.73	0.64
Error (%)	0.23	0.20
Acceptance value (AV) ³²	1.75	1.54
Max allowed AV (LI) ³²	15	(AV) ³²

Arrhenius equation was found to be:

$$\ln K = 2.747 - 5.025 \times 10^{-3}/T$$

where K is the rate constant and T is the temperature in Kelvin.

TABLE-9
EFFECT OF TEMPERATURE ON THE KINETIC PARAMETERS OF CANDESARTAN CILEXETIL USING 0.1 M NaOH

Medium	Temp. ($^{\circ}\text{C}$)	K (min^{-1})	T _{1/2} (min)	E _a (Kcal mol ⁻¹)
0.1 M NaOH	60	0.011	62.43	10.53
	70	0.0175	39.60	9.52
	80	0.026	26.65	10.19
	90	0.0388	17.86	X = 10.08

Fig. 3. Effect of different heating times with 0.1 M NaOH on the rate of degradation of candesartan cilexetil (10 $\mu\text{g/mL}$)

Fig. 4. Arrhenius plot for the degradation of candesartan cilexetil (10 $\mu\text{g/mL}$) in 0.1 M NaOH

The activation energy was calculated and found to be 10.08 Kcal/mol. This value is in accordance with the reported value of activation energy required for the hydrolysis of esters³³.

Conclusion

The proposed bivariate method provides simple, accurate and reproducible quantitative analysis for the determination of candesartan cilexetil in pharmaceutical tablets and in presence of its alkaline-induced degradation product, it is considered as a stability-indicating one. Thus, it can be used for the quality control of candesartan cilexetil in the commercial tablets with excellent application of content uniformity test. Moreover, the method is fast and feasible and has the advantages of being lower costing.

ACKNOWLEDGEMENTS

This project was supported by King Saud University, Deanship of Scientific Research, College of Science Research Center.

REFERENCES

1. K.L. McClellan and K.I. Goa, *Drugs*, **56**, 847 (1998).
2. C.H. Gleiter, C. Jagle, U. Gresser and K. Morike, *Cardiovas. Drugs Rev.*, **22**, 263 (2004).
3. N. Ferreira, S. Dresen, R.M. Alonso and W. Weinmann, *J. Chromatogr. B*, **855**, 134 (2007).
4. L. Gonzalez, J.A. Lopez, R.M. Alonso and R.M. Jimenez, *J. Chromatogr. A*, **949**, 49 (2002).
5. G. Iriarte, O. Gonzalez, N. Ferreira, M.I. Maguregui, R.M. Alonso and R.M. Jimenez, *J. Chromatogr. B*, **877**, 3045 (2009).
6. O. Gonzalez, G. Iriarte, N. Ferreira, M.I. Maguregui, R.M. Alonso and R.M. Jimenez, *J. Pharm. Biomed. Anal.*, **50**, 630 (2009).
7. S. Mehta, R.P. Shah, R. Priyadarshi and S. Singh, *J. Pharm. Biomed. Anal.*, **52**, 345 (2010).
8. D.V.S. Roa, P. Radhakrishnanand, M.V. Suryanarayana and V. Himabindu, *Chromatographia*, **66**, 499 (2007).
9. L.-J. Zhou, W. Dai, L.-H. Gu, Y.-J. Wang, Z.-Y. Huang and J.-Y. Liang, *Fudan Univ. J. Med. Sci.*, **35**, 552 (2008).
10. H. Stenhoft, P.O. Lagerstrom and C. Andersen, *J. Chromatogr. B*, **731**, 411 (1999).
11. N. Erk, *J. Liq. Chromatogr. Rel. Technol.*, **26**, 2581 (2003).
12. S.S. Qutab, S.N. Razzaq, M. Asfag, Z.A. Shuja and I.U. Khan, *Acta Chromatogr.*, **19**, 119 (2007).
13. A.E.M. Khedr, *King Abdulaziz Univ. Med. Sci.*, **15**, 3 (2008).
14. S. Hillaert and W. Van den Bossche, *J. Chromatogr. A*, **979**, 323 (2002).
15. S. Hillaert and W. Van den Bossche, *J. Pharm. Biomed. Anal.*, **31**, 329 (2003).
16. S. Hillaert, T.R.M. De Beer, J.O. De Beer and W. Van den Bossche, *J. Chromatogr. A*, **984**, 135 (2003).
17. M. Zhang, F. Wei, Y.F. Zhang, J. Nie and Y.Q. Feng, *J. Chromatogr. A*, **1102**, 294 (2006).
18. B. Dogan, B. Uslu and S.A. Ozkan, *Pharmazie*, **59**, 840 (2004).
19. I. Suslu, N. Ozaltın and S. Altınöz, *J. Appl. Electrochem.*, **39**, 1535 (2009).
20. I. Suslu, N. Ozaltın and S. Altınöz, *J. Assoc. Off. Anal. Chem. Int.*, **93**, 562 (2010).
21. B.H. Mehta and S.B. Morge, *J. Planar Chromatogr. Modern TLC*, **21**, 173 (2008).
22. N.A. Charoo, M. Bashir, E. Abdalla and K.I.H. Ali, *Anal. Lett.*, **42**, 2232 (2009).
23. N. Erk, *Pharmazie*, **58**, 796 (2003).
24. M. Stolarczyk, A. Maslanka, J. Krzek and J. Milczarek, *Acta Poloniae Pharm. Drug Res.*, **65**, 275 (2008).
25. ICH, Stability Testing of New Drugs Substances and Products International Conference on Harmonization, Geneva (1993).
26. P.L. Lopez-de-Alba, L.L. Martinez, K.W. Kaczmarzyc, K. Wrobel and J.A. Hernandez, *J. Anal. Lett.*, **29**, 487 (1996).
27. P.L. Lopez-de-Alba, L.L. Martinez, K.W. Kaczmarzyc, K. Wrobel and J.A. Hernandez, *Bol. Soc. Chilena Quim*, **41**, 111 (1996).
28. D.L. Massart, B.G.M. Vandeginste, S.N. Deming, Y. Michotte and L. Kaufman, *Chemometrics A Textbook*, Elsevier, Amsterdam, p. 124 (1988).
29. F.H. Metwally, *Spectrochim. Acta A*, **69**, 343 (2008).
30. ICH.Q2 (R1) Validation of Analytical Procedures: Test and Methodology, International Conference on Harmonization, Geneva (2005).
31. J.C. Miller and J.N. Miller, *Statistics for Analytical Chemistry*, Ellis-Howood New York, edn. 4, p. 115 (1993).
32. The United States Pharmacopeia 30, The National Formulary, 25, (2007); US Pharmacopeial Convention; Rockville, MD, Electronic version.
33. K.A. Connors, G.L. Amidon and L. Kennon, In *Chemical Stability of Pharmaceuticals*, John Wiley & Sons, New York, p. 20 (1979).